A case-control study of fibrinolytic activity was conducted comparing 12 women with a recent
history of thromboembolism while taking oral contraceptives and 28 matched female …

Screening for thrombophilia in women candidate to the pill is still a matter of debate. Oral
contraceptives may trigger venous thromboembolic events in carriers of common inherited …

Objective: Three research articles published in late 1995 and early 1996 suggested that oral
contraceptives containing either of the newer progestogens (gestodene or desogestrel) …

The objective of this paper was to assess the risk of thrombosis in users of oral
contraceptives. Furthermore, the sensitivity, specificity and predictive values of potential …

Factor V Leiden and factor II G20210A mutations are two frequent genetic risk factors
involved in venous thromboembolism (VTE). The goal of this pooled analysis of 8 case …

Exogenous hormone therapies, such as combined oral contraceptives (COC) and hormone
replacement therapy (HRT), cause blood hypercoagulability and are a risk factor for venous …

Oral contraceptives (OC) are either composed of a combination of an estrogen derivative
(usually ethinly estradiol) and a progestogen, or they contain a progestogen only. OC are …

Oral contraceptive therapy is associated with a fourfold increased risk of venous
thromboembolism as compared with agematched non-users. The composition of oral …

Background Two studies recently published in the British Medical Journal, a retrospective
cohort study using information from the Danish registries1 and the MEGA case-control study …

Combined oral contraceptives, oral hormone replacement therapy and thrombophilias are
recognised risk factors for venous thromboembolism in women. The objective of this study …